Literature DB >> 15220833

[Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis].

Amélie Carbonnelle1, Richard Delarue, Danielle Canioni, Nicole Brousse.   

Abstract

Nodular lymphocyte predominance Hodgkin's disease (NLPHD), previously called nodular paragranuloma, is a rare entity recognized as a clinico-pathological entity distinct from classic Hodgkin's lymphoma. It is an indolent B cell lymphoma derived from a germinal center cell. NLPHD may closely resemble lymphocyte-rich classic Hodgkin's disease (LR-CHD) or T-cell or histiocyte-rich large B-cell lymphoma (TCRLBCL). A reproducible distinction between these entities is difficult but the classification is prognostically relevant. NLPHD is characterized by neoplastic "popcorn" cells CD20+ CD30- CD15- EMA+ Bcl6+ scattered within a nodular background predominantly composed of small B lymphocytes. LR-CHD neoplastic proliferation is composed of CD20+/- CD30+ CD15+/- EMA- Bcl6+/- Reed Sternberg or Hodgkin's cells, scattered within numerous CD3+ T cells. TCRLBCL is an agressive lymphoma composed of CD20+ CD30- CD15- EMA+/- Bcl6+/- polymorphic neoplastic cells, scattered within a mixture of CD3+ T cells and histiocytes. Epstein Barr virus is detectable within half cases of LR-CHD, but never in NLPHD and rarely in TCRLBCL. The transcription factors BOB1, PU-1, BSAP and IRF4 are new markers that could be useful for differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220833     DOI: 10.1016/s0242-6498(04)93937-5

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  1 in total

1.  Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkin's lymphoma.

Authors:  Stephanie Roggerone; Alexandra Traverse-Glehen; Laurent Derex; Jerome Honnorat; Francoise Berger; Gilles Salles; Hugues Rousset; Paul Trouillas; Norbert Nighoghossian
Journal:  J Neurooncol       Date:  2008-05-07       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.